July 6, 2021

Mir Imran President and Chief Executive Officer Rani Therapeutics Holdings, Inc. 2051 Ringwood Avenue San Jose, CA 95131

Holdings, Inc.

Re: Rani Therapeutics

Amendment No. 1 to Draft Registration

Statement on Form S-1

Submitted June 22,

CIK No. 0001856725

2021

Dear Mr. Imran:

We have reviewed your amended draft registration statement and have the following

comment. In our comment we may ask you to provide us with information so we may better

understand your disclosure.

Please respond to this letter by providing the requested information and either submitting

an amended draft registration statement or publicly filing your registration statement on

EDGAR. If you do not believe our comment applies to your facts and circumstances or do not

believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to this comment and your

amended draft registration statement or filed registration statement, we may have additional

comments.

Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted June 22, 2021

Intellectual Property, page 168

We note the revised disclosure provided in response to our prior comment 14 and we reissue the comment in part. In relation to the company's material patents, please further revise your intellectual property disclosure to clearly describe on an individual or patent family basis the type of patent protection granted for each product or technology (composition of matter, use, or process), the expiration year of each patent, and the jurisdiction, including any foreign jurisdiction, of each material pending or issued patent.

In this regard, it may

be useful to provide this disclosure in tabular form to support the

Mir Imran Rani Therapeutics Holdings, Inc.

July 6, 2021 Page 2

narrative already included.

You may contact Kevin Kuhar at 202-551-3662 or Tracey McKoy at 202-551-3772 if

you have questions regarding comments on the financial statements and related matters. Please

contact Lauren Hamill at 303-844-1008 or Laura Crotty at 202-551-7614 with any other

questions.

FirstName LastNameMir Imran

Corporation Finance Comapany NameRani Therapeutics Holdings, Inc.

Sciences
July 6, 2021 Page 2
cc: Josh Seidenfeld
FirstName LastName

Sincerely,

Division of

Office of Life